Clinical Trial of Oral Nelfinavir Before and During Radiation Therapy for Advanced Rectal Cancer

PURPOSE: Nelfinavir, a PI3-kinase pathway inhibitor, is a radiosensitizer which increases tumor blood flow in preclinical models. We conducted an early-phase study to demonstrate the safety of nelfinavir combined with hypofractionated radiotherapy (RT) and to develop biomarkers of tumor perfusion an...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Clin Cancer Res
Päätekijät: Hill, Esme J., Roberts, Corran, Franklin, Jamie M., Enescu, Monica, West, Nicholas, MacGregor, Thomas P., Chu, Kwun-Ye, Boyle, Lucy, Blesing, Claire, Wang, Lai-Mun, Mukherjee, Somnath, Anderson, Ewan M., Brown, Gina, Dutton, Susan, Love, Sharon B., Schnabel, Julia A., Quirke, Phil, Muschel, Ruth, McKenna, William G., Partridge, Michael, Sharma, Ricky A.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2016
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4835023/
https://ncbi.nlm.nih.gov/pubmed/26861457
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-1489
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia